Biocon Launches Two New Biosimilars in the U.S. Market
Biocon rolls out two biosimilars in US market
The Economic Times
Image: The Economic Times
Biocon Ltd has launched two biosimilars, Bosaya and Aukelso, in the U.S. market, targeting serious bone conditions. Both products received FDA approval in September 2025, allowing for pharmacy-level substitution, thereby expanding access to affordable treatment options for patients.
- 01Biocon launched two biosimilars, Bosaya and Aukelso, in the U.S.
- 02Both products target serious bone conditions and are available by prescription.
- 03The U.S. FDA approved these biosimilars in September 2025.
- 04Bosaya is a biosimilar to Prolia, while Aukelso is a biosimilar to Xgeva.
- 05This launch reflects Biocon's commitment to expanding access to affordable healthcare.
Advertisement
In-Article Ad
Biocon Ltd, based in New Delhi, has officially launched two biosimilars, Bosaya and Aukelso, in the U.S. market, aimed at treating serious bone conditions. Both products received approval and an interchangeable designation from the U.S. Food and Drug Administration (FDA) in September 2025, which allows for substitution at the pharmacy level according to state regulations. Bosaya, a biosimilar to Prolia, is available in a 60 mg/mL injection format, while Aukelso, a biosimilar to Xgeva, comes in a 120 mg/1.7 mL single-dose vial. Biocon's CEO, Shreehas Tambe, emphasized that this launch signifies a strategic expansion of their biosimilars portfolio, reinforcing their leadership in oncology and immunology and enhancing access to affordable treatment options for patients in the U.S. and globally.
Advertisement
In-Article Ad
The introduction of these biosimilars increases access to affordable treatment options for patients with serious bone conditions, potentially improving health outcomes.
Advertisement
In-Article Ad
Reader Poll
Do you believe biosimilars will improve access to affordable healthcare?
Connecting to poll...
Read the original article
Visit the source for the complete story.